Linezolid Krka D.D. (Linezolid)

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This action stops bacterial growth, providing a bacteriostatic effect against susceptible Gram‑positive organisms, including MRSA and VRE.

The prescribed dose of linezolid is determined by the treating physician based on the type and severity of infection, patient weight, renal and hepatic function, and any concomitant medications. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for linezolid in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details and any required import documentation.

Linezolid offers oral bioavailability and activity against MRSA and VRE, whereas vancomycin, a glycopeptide, is administered intravenously and may be less effective against some resistant strains. Daptomycin is another alternative but is not suitable for pneumonia. Linezolid’s convenient oral route and broad Gram‑positive coverage make it a valuable option in many clinical scenarios.

Linezolid tablets should be stored at temperatures below 25 °C, in the original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Linezolid is administered orally as a tablet that should be swallowed whole with water. It can be taken with or without food. The exact dosing schedule is set by the prescriber and may be once or twice daily depending on the infection.

Serious adverse events include thrombocytopenia, peripheral neuropathy, serotonin syndrome (especially when combined with serotonergic drugs), lactic acidosis, and optic neuritis. Patients should be monitored regularly for blood count changes and any new neurological symptoms.

Linezolid is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. It should also be avoided in individuals currently receiving monoamine oxidase inhibitors (MAOIs) or those with uncontrolled hypertension when consuming tyramine‑rich foods.